When it comes to NVDA… “acceleration cycles” are the key

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Nicholas Keen Biography and Net Worth

Insider of Bicycle Therapeutics

Nick Keen, Ph.D., is chief scientific officer of Bicycle Therapeutics. He joined Bicycle from Novartis, where for the past five years he served as the Cambridge (U.S.) head of oncology research. During his tenure at Novartis, Nick was responsible for leading research from basic target identification and drug discovery through to enabling early clinical trials. Under his leadership, the group delivered multiple new therapies to the clinic, spanning the range from novel allosteric small molecule inhibitors of previously intractable targets to advanced biologic therapies. Nick’s team was also responsible for publishing many basic discoveries in cancer biology and for building industry leading platforms in whole genome scale target identification and in modeling the diversity of human clinical trials in mice.

Prior to his time at Novartis, Nick led the early lead generation group for oncology at AstraZeneca’s U.S. research site, with a particular focus on epigenetic regulation, and prior to this, held positions of increasing responsibility in AstraZeneca’s U.K. oncology research group. During his time at AstraZeneca, Nick delivered multiple agents to the clinic and was instrumental in the acquisition of KuDOS Pharmaceuticals, leading to the registration of Olaparib (a first in class PARP inhibitor) for the treatment of BRCA mutant cancers.

Nick completed his undergraduate studies at the University of Cambridge in natural sciences, his graduate studies with the Imperial Cancer Research Fund in Cambridge (now merged with The Cancer Research Campaign to form Cancer Research UK) and his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.

What is Nicholas Keen's net worth?: The estimated net worth of Nicholas Keen is at least $1.28 million as of April 3rd, 2024. Dr. Keen owns 62,803 shares of Bicycle Therapeutics stock worth more than $1,278,669 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Keen may own. Learn More about Nicholas Keen's net worth.
How old is Nicholas Keen?: Dr. Keen is currently 56 years old. There are 5 older executives and no younger executives at Bicycle Therapeutics. The oldest executive at Bicycle Therapeutics is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director, who is 73 years old. Learn More on Nicholas Keen's age.
How do I contact Nicholas Keen?: The corporate mailing address for Dr. Keen and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Nicholas Keen's contact information.
Has Nicholas Keen been buying or selling shares of Bicycle Therapeutics?: Nicholas Keen has not been actively trading shares of Bicycle Therapeutics during the past quarter. Most recently, Nicholas Keen sold 790 shares of the business's stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a transaction totalling $18,809.90. Following the completion of the sale, the insider now directly owns 62,803 shares of the company's stock, valued at $1,495,339.43. Learn More on Nicholas Keen's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, insiders at the sold shares 17 times. They sold a total of 32,657 shares worth more than $683,852.68. The most recent insider tranaction occured on November, 11th when CAO Travis Alvin Thompson sold 6,256 shares worth more than $157,088.16. Insiders at Bicycle Therapeutics own 8.5% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 11/11/2024.

Nicholas Keen Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2024	Sell	790	$23.81	$18,809.90	62,803
10/3/2023	Sell	272	$20.00	$5,440.00	38,233
7/3/2023	Sell	336	$25.10	$8,433.60	38,505
4/3/2023	Sell	319	$21.11	$6,734.09	38,841
3/31/2021	Sell	10,000	$30.00	$300,000.00	28,321
3/15/2021	Sell	217	$28.00	$6,076.00	38,821
3/12/2021	Sell	9,783	$28.50	$278,815.50	38,821

Nicholas Keen Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $20.36

$20.15

$20.90

50 Day Range

MA: $24.37

$20.46

$27.51

2 Week Range

Now: $20.36

$13.07

$28.67

Volume

270,591 shs

Average Volume

358,656 shs

Market Capitalization

$968.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

When it comes to NVDA… “acceleration cycles” are the key

From DTI | Ad